PMID- 32045161
OWN - NLM
STAT- MEDLINE
DCOM- 20200403
LR  - 20200403
IS  - 1087-2108 (Electronic)
IS  - 1087-2108 (Linking)
VI  - 25
IP  - 12
DP  - 2019 Dec 15
TI  - Drug-induced anti-Ro positive subacute cutaneous lupus in a man treated with 
      olmesartan.
LID - 13030/qt3xf8k540 [pii]
AB  - A 66-year-old man presented to the outpatient dermatology clinic with a chief 
      complaint of a pruritic rash on his upper trunk and proximal upper extremities, 
      which had been present for three weeks. Upon examination, he was found to have an 
      erythematous, annular, and polycyclic eruption on the chest, upper back, and 
      proximal extremities. A clinical diagnosis of subacute cutaneous lupus 
      erythematosus (SCLE) was made. The patient was found to have a positive 
      anti-nuclear antibody (ANA) in a speckled pattern and a positive anti-Ro 
      antibody. A biopsy revealed an interface and lichenoid dermatitis with dermal 
      mucin deposition, consistent with subacute cutaneous lupus erythematosus. The 
      patient reported that he had recently been diagnosed with hypertension and began 
      treatment with olmesartan, a potassium-sparing diuretic that blocks the 
      angiotensin II receptor, commonly used as an antihypertensive or in patients with 
      heart failure. Cutaneous reactions to olmesartan are rare and reported in <1% 
      of patients in post-marketing surveillance. The patient discontinued use of 
      olmesartan and the rash completely resolved within three weeks. To date, there 
      are no other reported cases of drug induced SCLE in patients taking olmesartan to 
      our knowledge.
FAU - Gray, Taylor
AU  - Gray T
AD  - Hospital Corporation of America/University of South Florida Morsani College of 
      Medicine Graduate Medical Education: Department of Dermatology, Largo Medical 
      Center Program, Largo, FL. etaylorgray2018@gmail.com.
FAU - Segars, Kelly
AU  - Segars K
FAU - Farsi, Maheera
AU  - Farsi M
FAU - Ross, Risa
AU  - Ross R
FAU - Miller, Richard
AU  - Miller R
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20191215
PL  - United States
TA  - Dermatol Online J
JT  - Dermatology online journal
JID - 9610776
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Imidazoles)
RN  - 0 (SS-A antibodies)
RN  - 0 (Tetrazoles)
RN  - 8W1IQP3U10 (olmesartan)
SB  - IM
MH  - Aged
MH  - Angiotensin II Type 1 Receptor Blockers/*adverse effects
MH  - Antibodies, Antinuclear/blood
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Imidazoles/*adverse effects
MH  - Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis/pathology
MH  - Male
MH  - Skin/pathology
MH  - Tetrazoles/*adverse effects
EDAT- 2020/02/12 06:00
MHDA- 2020/04/04 06:00
CRDT- 2020/02/12 06:00
PHST- 2020/01/27 00:00 [received]
PHST- 2020/01/27 00:00 [accepted]
PHST- 2020/02/12 06:00 [entrez]
PHST- 2020/02/12 06:00 [pubmed]
PHST- 2020/04/04 06:00 [medline]
AID - 13030/qt3xf8k540 [pii]
PST - epublish
SO  - Dermatol Online J. 2019 Dec 15;25(12):13030/qt3xf8k540.